The new round follows a EUR 4.3 million financing completed in spring 2025. Omnio’s therapy is based on research by Tor Ny, Professor Emeritus of Medical Biochemistry at Umeå University and Head of R&D at the company. Its lead indication is diabetic foot ulcers (DFU), a condition with few effective treatment options.

More than half a billion people worldwide live with diabetes, and up to one-third will develop a foot ulcer during their lifetime. These wounds can become chronic, limiting mobility and putting patients at risk of amputation. Advanced-stage DFU costs healthcare systems an estimated EUR 50,000 per wound episode.

“This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies,” says Felipe Velasquez, CEO of Omnio.

The company has established its master cell bank and is now scaling up manufacturing for a GMP batch. That batch will be used in the toxicology studies required before Omnio can apply to start clinical trials. The clinical program will begin with a Phase I/IIa study of safety and early efficacy in patients with DFU.

“Our ambition is to move into patient studies during 2027. We are already evaluating CROs, investigators, and trial countries across Europe to support the launch of the clinical program,” says Velasquez.

Beyond DFU, Omnio sees potential for its platform in venous leg ulcers, burns, tympanic membrane perforations, infection, and periodontitis.

“The wound healing market is mostly a medical devices market, but nothing has really moved the needle in hard-to-heal wounds,” he says. “We are not developing another medical device. We are developing a biologic therapy that addresses the biology of wound healing and the root cause of why these wounds stay open.”

R&D stays in Umeå, while clinical operations and quality functions are run from Copenhagen and Barcelona. Omnio plans to open its next financing round in Q1 2027 to fund clinical development through first efficacy data.